Liver/Biliary Disorders News

SAN DIEGO — Once-daily FXR314 was well-tolerated and safely improved liver fat content and biochemical markers over 16 weeks in patients with metabolic dysfunction-associated steatohepatitis, according to research at The Liver Meeting.

SAN DIEGO — Glucagon-like peptide-1 receptor agonists may help alleviate risk for adverse liver outcomes, particularly hepatic decompensation, among patients with type 2 diabetes and alcohol-associated liver disease.

SAN DIEGO — Increasing the mean arterial pressure target to 75 mmHg lowered the odds of 28-day mortality by 85%, and also reduced the odds of acute kidney injury nonrecovery, in decompensated cirrhosis with septic shock, according to data.

SAN DIEGO — Retreatment with nucleos(t)ide analogue therapy for relapse after withdrawal did not affect hepatitis B surface antigen seroclearance among patients with chronic HBV infection, according to a researcher at The Liver Meeting.

SAN DIEGO — Preemptive continuous renal replacement therapy after therapeutic plasma exchange reduced mortality and improved other outcomes in patients with acute liver failure and cerebral edema, according to data from The Liver Meeting.

PHILADELPHIA — Mycophenolate mofetil appeared to be more efficacious and tolerable than azathioprine in patients with autoimmune hepatitis, especially among those aged older than 50 years and with lower IgG levels, according to a presenter.

PHILADELPHIA — In this video, Nancy S. Reau, MD, FAASLD, AGAF, discusses the impact certain herbal and dietary supplements may have on the liver, especially among patients with underlying liver disease.

PHILADELPHIA — Pharmacologic therapy for alcohol use disorder may be an “underutilized treatment modality,” especially in patients with related liver disease, according to research presented at the ACG Annual Scientific Meeting.

PHILADELPHIA — In this video, Nancy S. Reau, MD, FAASLD, AGAF, highlights a presentation at the ACG Annual Scientific Meeting investigating the use of Livdelzi in patients with primary biliary cholangitis and cirrhosis.

PHILADELPHIA — In this video, Nancy S. Reau, MD, FAASLD, AGAF, speaks with Healio about findings from a systemic review and meta-analysis on the efficacy of mycophenolate mofetil compared with azathioprine for autoimmune hepatitis.